{
    "clinical_study": {
        "@rank": "33591", 
        "arm_group": {
            "arm_group_label": "Avastin", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the efficacy and safety of Avastin (5mg/kg iv, every 2 weeks) in\n      patients with multiple myeloma, relapsed/refractory after at least 2 lines of prior therapy.\n      The anticipated time on study treatment is 3 months - 1 year."
        }, 
        "brief_title": "A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma", 
        "completion_date": {
            "#text": "March 2009", 
            "@type": "Actual"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  adult patients, 19-75 years of age;\n\n          -  multiple myeloma;\n\n          -  progressive disease after at least 2 lines of prior therapy.\n\n        Exclusion Criteria:\n\n          -  non-secretory myeloma;\n\n          -  history of malignancy, other than squamous cell cancer, basal cell cancer, or cancer\n             in situ of the cervix within the last 5 years;\n\n          -  major surgical procedure, open biopsy, or significant traumatic injury within 28 days\n             prior to study treatment start;\n\n          -  clinically significant cardiac disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02079519", 
            "org_study_id": "ML18704"
        }, 
        "intervention": {
            "arm_group_label": "Avastin", 
            "description": "5 mg/kg intravenously every 2 weeks", 
            "intervention_name": "bevacizumab [Avastin]", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Salzburg", 
                        "country": "Austria", 
                        "zip": "5020"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wien", 
                        "country": "Austria", 
                        "zip": "1140"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wien", 
                        "country": "Austria", 
                        "zip": "1090"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wien", 
                        "country": "Austria", 
                        "zip": "1160"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label Study of the Effect of Avastin on Overall Response in Patients With Relapsed/Refractory Multiple Myeloma", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Chair"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "Austria: Bundesamt f\u00fcr Sicherheit im Gesundheitswesen"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Overall response (complete and partial response)", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02079519"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2006", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014", 
        "why_stopped": "The study was discontinued prematurely by the sponsor due to a lack of recruitment."
    }
}